Comprehensive Stock Comparison
Compare Azitra, Inc. (AZTR) vs BiomX Inc. (PHGE) vs Armata Pharmaceuticals, Inc. (ARMP) vs Seres Therapeutics, Inc. (MCRB) vs Evogene Ltd. (EVGN) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  MCRB | 448.4% revenue growth vs AZTR's -100.0% |
| Quality / Margins | MCRB | 15.4% net margin vs ARMP's -9.3% |
| Stability / Safety |  ARMP | Beta 0.21 vs MCRB's 1.21 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | ARMP | +474.8% vs AZTR's -91.7% |
| Efficiency (ROA) | MCRB | 3.8% ROA vs PHGE's -142.8%, ROIC -180.9% vs -305.2% |
Who Each Stock Is For
Income & stability
ARMPDividend streak 0 yrs, beta 0.21
Growth exposure
EVGNRev growth 50.9%, EPS growth 44.7%, 3Y rev CAGR 109.2%
Long-term compounding (10Y)
ARMP-98.0% 10Y total return vs MCRB's -98.5%
Sleep-well-at-night portfolio
AZTRLower volatility, beta 0.65, Low D/E 11.1%, current ratio 2.83x
Defensive / Recession hedge
AZTRBeta 0.65, current ratio 2.83x
Business Model
What each company does and how it makes money
Azitra is a preclinical biopharmaceutical company developing engineered bacterial therapies for rare and serious skin diseases. It aims to generate revenue through drug development partnerships and future product sales — though currently in preclinical stages without commercial revenue. The company's key advantage lies in its proprietary platform for engineering commensal skin bacteria to deliver therapeutic proteins directly to diseased skin.
BiomX is a clinical-stage biotechnology company developing targeted phage therapies — viruses that kill specific harmful bacteria — for chronic diseases and skin conditions. It generates no commercial revenue yet but is funded through equity offerings and partnerships to advance its pipeline, which includes therapies for cystic fibrosis, inflammatory bowel diseases, and atopic dermatitis. The company's key advantage is its proprietary platform for discovering and engineering natural phages that precisely target disease-causing bacteria while sparing beneficial microbes.
Armata Pharmaceuticals is a clinical-stage biotech company developing targeted bacteriophage therapies to treat antibiotic-resistant bacterial infections. It generates revenue primarily through research collaborations and partnerships — like its Merck deal — while advancing its pipeline of phage-based candidates through clinical trials. The company's key advantage is its proprietary bacteriophage platform technology, which offers a novel approach to targeting specific drug-resistant pathogens.
Seres Therapeutics is a microbiome therapeutics company developing bacterial consortia treatments for serious diseases. It generates revenue primarily through collaboration agreements and milestone payments — notably with Nestlé Health Science — while advancing its lead candidate SER-109 toward FDA approval for recurrent C. difficile infection. The company's key advantage is its proprietary platform for rationally designing bacterial consortia that functionally interact with human biology, creating a technical moat in the emerging microbiome therapeutics field.
Evogene is a computational biology company that uses its proprietary AI-powered platform to discover and develop products across agriculture, human health, and industrial applications. It generates revenue through research collaborations, licensing agreements, and milestone payments from partners—primarily in agriculture (~70% of focus) and human health (~30%). The company's key advantage is its Computational Predictive Biology platform, which leverages big data and machine learning to accelerate product discovery in life sciences with higher precision than traditional methods.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 5 stocks. BestLagging
Financial Scorecard
ARMP 2AZTR 1EVGN 1
PHGE 0MCRB 0EVGN3/6 metricsAZTR4/9 metricsARMP5/6 metricsARMP2/2 metricsARMP leads in 2 of 6 categories (Total Returns, Risk & Volatility). EVGN leads in 1 (Financial Metrics). 1 tied.
Financial Metrics (TTM)
EVGN and PHGE operate at a comparable scale, with $5M and $0 in trailing revenue. MCRB is the more profitable business, keeping 15.4% of every revenue dollar as net income compared to ARMP's -9.3%. On growth, ARMP holds the edge at -61.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | AZTRAzitra, Inc. | PHGEBiomX Inc. | ARMPArmata Pharmaceut… | MCRBSeres Therapeutic… | EVGNEvogene Ltd. |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $0 | $5M | $351,000 | $5M |
| EBITDAEarnings before interest/tax | -$11M | -$6M | -$32M | -$99M | -$13M |
| Net IncomeAfter-tax profit | -$11M | -$37M | -$47M | $5M | -$3M |
| Free Cash FlowCash after capex | -$86M | -$28M | -$27M | -$23M | -$17M |
| Gross MarginGross profit ÷ Revenue | — | — | +70.5% | -50.1% | +16.1% |
| Operating MarginEBIT ÷ Revenue | — | — | -6.6% | -294.7% | -2.8% |
| Net MarginNet income ÷ Revenue | — | — | -9.3% | +15.4% | -52.3% |
| FCF MarginFCF ÷ Revenue | — | — | -5.4% | -66.6% | -3.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | -61.0% | — | -82.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -6.9% | -6.5% | -3.9% | +112.3% | +133.6% |
Valuation Metrics
| Metric | AZTRAzitra, Inc. | PHGEBiomX Inc. | ARMPArmata Pharmaceut… | MCRBSeres Therapeutic… | EVGNEvogene Ltd. |
|---|---|---|---|---|---|
| Market CapShares × price | $2M | $82.8B | $420M | $80M | $7M |
| Enterprise ValueMkt cap + debt − cash | -$1.6B | $82.8B | $537M | $141M | $5M |
| Trailing P/EPrice ÷ TTM EPS | -0.08x | -4.29x | -22.19x | -0.48x | -0.29x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — | 81.14x | — | 0.86x |
| Price / BookPrice ÷ Book value/share | 0.00x | 3427.64x | — | 5.15x | 0.32x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | — |
Profitability & Efficiency
MCRB delivers a 12.3% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $-4 for PHGE. AZTR carries lower financial leverage with a 0.11x debt-to-equity ratio, signaling a more conservative balance sheet compared to MCRB's 6.65x. On the Piotroski fundamental quality scale (0–9), PHGE scores 3/9 vs AZTR's 1/9, reflecting mixed financial health.
| Metric | AZTRAzitra, Inc. | PHGEBiomX Inc. | ARMPArmata Pharmaceut… | MCRBSeres Therapeutic… | EVGNEvogene Ltd. |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -0.3% | -3.6% | — | +12.3% | -15.9% |
| ROA (TTM)Return on assets | -0.2% | -142.8% | -52.4% | +3.8% | -10.5% |
| ROICReturn on invested capital | -0.8% | -3.1% | -44.2% | -180.9% | -102.4% |
| ROCEReturn on capital employed | -0.6% | -159.9% | -70.7% | -67.7% | -66.5% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 3 | 2 | 2 | 3 |
| Debt / EquityFinancial leverage | 0.11x | 0.40x | — | 6.65x | 0.87x |
| Net DebtTotal debt minus cash | -$1.6B | -$8M | $117M | $61M | -$2M |
| Cash & Equiv.Liquid assets | $2.1B | $18M | $9M | $31M | $15M |
| Total DebtShort + long-term debt | $422M | $10M | $127M | $92M | $13M |
| Interest CoverageEBIT ÷ Interest expense | -13.79x | -36.86x | -2.12x | — | -4.42x |
Total Returns (with DRIP)
A $10,000 investment in ARMP five years ago would be worth $25,857 today (with dividends reinvested), compared to $2 for AZTR. Over the past 12 months, ARMP leads with a +474.8% total return vs AZTR's -91.7%. The 3-year compound annual growth rate (CAGR) favors ARMP at 56.0% vs AZTR's -94.2% — a key indicator of consistent wealth creation.
| Metric | AZTRAzitra, Inc. | PHGEBiomX Inc. | ARMPArmata Pharmaceut… | MCRBSeres Therapeutic… | EVGNEvogene Ltd. |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -32.1% | +194.4% | +77.0% | -39.7% | -25.8% |
| 1-Year ReturnPast 12 months | -91.7% | -48.8% | +474.8% | -40.3% | -40.6% |
| 3-Year ReturnCumulative with dividends | -100.0% | -93.2% | +279.4% | -91.7% | -88.8% |
| 5-Year ReturnCumulative with dividends | -100.0% | -99.5% | +158.6% | -97.6% | -98.2% |
| 10-Year ReturnCumulative with dividends | -100.0% | -99.7% | -98.0% | -98.5% | -98.8% |
| CAGR (3Y)Annualised 3-year return | -94.2% | -59.1% | +56.0% | -56.4% | -51.8% |
Risk & Volatility
ARMP is the less volatile stock with a 0.21 beta — it tends to amplify market swings less than MCRB's 1.21 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ARMP currently trades 71.1% from its 52-week high vs AZTR's 7.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AZTRAzitra, Inc. | PHGEBiomX Inc. | ARMPArmata Pharmaceut… | MCRBSeres Therapeutic… | EVGNEvogene Ltd. |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.65x | 0.93x | 0.21x | 1.21x | 0.54x |
| 52-Week HighHighest price in past year | $2.66 | $14.71 | $16.34 | $29.98 | $2.42 |
| 52-Week LowLowest price in past year | $0.15 | $1.56 | $0.90 | $6.53 | $0.81 |
| % of 52W HighCurrent price vs 52-week peak | +7.1% | +42.8% | +71.1% | +30.5% | +34.6% |
| RSI (14)Momentum oscillator 0–100 | 35.7 | 51.0 | 71.9 | 32.0 | 36.0 |
| Avg Volume (50D)Average daily shares traded | 1.4M | 1.3M | 50K | 70K | 547K |
Analyst Outlook
Analyst consensus: ARMP as "Buy", MCRB as "Buy". Consensus price targets imply -22.5% upside for ARMP (target: $9) vs -86.3% for MCRB (target: $1).
| Metric | AZTRAzitra, Inc. | PHGEBiomX Inc. | ARMPArmata Pharmaceut… | MCRBSeres Therapeutic… | EVGNEvogene Ltd. |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | Buy | Buy | — |
| Price TargetConsensus 12-month target | — | — | $9.00 | $1.25 | — |
| # AnalystsCovering analysts | — | — | 4 | 18 | — |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | 0 | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Jun 23 | Mar 26 | Change |
|---|---|---|---|
| Azitra, Inc. (AZTR) | 100 | 0.02 | -100.0% |
| BiomX Inc. (PHGE) | 100 | 5.91 | -94.1% |
| Armata Pharmaceutic… (ARMP) | 100 | 984.48 | +884.5% |
| Seres Therapeutics,… (MCRB) | 100 | 9.14 | -90.9% |
| Evogene Ltd. (EVGN) | 100 | 7.45 | -92.6% |
Armata Pharmaceutic… (ARMP) returned +159% over 5 years vs Azitra, Inc. (AZTR)'s -100%. A $10,000 investment in ARMP 5 years ago would be worth $25,857 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Azitra, Inc. (AZTR) | $110000.00 | $0.00 | -100.0% |
| BiomX Inc. (PHGE) | $0.00 | $0.00 | — |
| Armata Pharmaceutic… (ARMP) | $260000.00 | $5M | +1890.0% |
| Seres Therapeutics,… (MCRB) | $22M | $0.00 | -100.0% |
| Evogene Ltd. (EVGN) | $7M | $9M | +30.1% |
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Azitra, Inc. (AZTR) | -81.3% | -119.6% | -47.1% |
| Armata Pharmaceutic… (ARMP) | -108.6% | -3.7% | +96.6% |
| Seres Therapeutics,… (MCRB) | -4.2% | -45.2% | -975.5% |
| Evogene Ltd. (EVGN) | -154.7% | -193.7% | -25.2% |
Armata Pharmaceuticals, Inc.'s net margin went from -109% (2015) to -4% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Azitra, Inc. (AZTR) | -3.33 | -2.25 | +32.5% |
| BiomX Inc. (PHGE) | -3.27 | -1.47 | +55.0% |
| Armata Pharmaceutic… (ARMP) | -345.8 | -0.52 | +99.8% |
| Seres Therapeutics,… (MCRB) | -46 | -18.86 | +59.0% |
| Evogene Ltd. (EVGN) | -0.77 | -2.89 | -275.3% |
Chart 5Free Cash Flow — 5 Years
Azitra, Inc. generated $-11B FCF in 2025 (-128900% vs 2021). BiomX Inc. generated $-37M FCF in 2024 (-18% vs 2021).
AZTR vs PHGE vs ARMP vs MCRB vs EVGN: Key Questions Answered
7 questions · data-driven answers · updated daily
01Is AZTR or PHGE or ARMP or MCRB or EVGN a better buy right now?
Analysts rate Armata Pharmaceuticals, Inc. (ARMP) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AZTR or PHGE or ARMP or MCRB or EVGN?
Over the past 5 years, Armata Pharmaceuticals, Inc. (ARMP) delivered a total return of +158.6%, compared to -100.0% for Azitra, Inc. (AZTR). A $10,000 investment in ARMP five years ago would be worth approximately $26K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ARMP returned -98.0% versus AZTR's -100.0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AZTR or PHGE or ARMP or MCRB or EVGN?
By beta (market sensitivity over 5 years), Armata Pharmaceuticals, Inc. (ARMP) is the lower-risk stock at 0.21β versus Seres Therapeutics, Inc.'s 1.21β — meaning MCRB is approximately 470% more volatile than ARMP relative to the S&P 500. On balance sheet safety, Azitra, Inc. (AZTR) carries a lower debt/equity ratio of 11% versus 7% for Seres Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — AZTR or PHGE or ARMP or MCRB or EVGN?
Seres Therapeutics, Inc. (MCRB) is the more profitable company, earning 1537% net margin versus -365.6% for Armata Pharmaceuticals, Inc. — meaning it keeps 1537% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AZTR leads at 0.0% versus -294.7% for MCRB. At the gross margin level — before operating expenses — EVGN leads at 39.8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — AZTR or PHGE or ARMP or MCRB or EVGN?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is AZTR or PHGE or ARMP or MCRB or EVGN better for a retirement portfolio?
For long-horizon retirement investors, Armata Pharmaceuticals, Inc. (ARMP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.21)). Both have compounded well over 10 years (ARMP: -98.0%, MCRB: -98.5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between AZTR and PHGE and ARMP and MCRB and EVGN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.